Nektar Therapeutics (NKTR) Share-based Compensation (2010 - 2026)

Nektar Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 13.93% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.1 million (down 37.95% YoY), and the FY2025 full-year result was $12.6 million, down 41.47% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.4 million, up from $2.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $21.0 million in Q1 2022, with the low at $2.2 million in Q4 2025.
• Average Share-based Compensation over 5 years is $7.5 million, with a median of $6.0 million recorded in 2024.
• Year-over-year, Share-based Compensation fell 12.29% in 2022 and slumped 54.34% in 2025.
• Tracing NKTR's Share-based Compensation over 5 years: stood at $12.7 million in 2022, then slumped by 43.05% to $7.3 million in 2023, then sank by 33.79% to $4.8 million in 2024, then tumbled by 54.34% to $2.2 million in 2025, then jumped by 52.99% to $3.4 million in 2026.
• The last three Share-based Compensation figures came in at $3.4 million (Q1 2026), $2.2 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.

Peer Comparison